CORONAVIT was a phase 3 randomized controlled trial, investigating the potential of vitamin D to reduce incidence and severity of acute respiratory infections (ARI) and COVID-19. touchRESPIRATORY were delighted to speak with Professor Adrian Martineau (Queen Mary University of London, London, UK) to learn more around the aims, design and outcome measures of the phase 3 CORONAVIT study and why vitamin D replacement failed to reduce risk of all-cause ARI or COVID-19 in this study.
The abstract ‘Vitamin D to prevent COVID-19 or other acute respiratory infections: phase 3 randomised controlled trial (CORONAVIT).’ (Abstract number: OA3795) was presented at ERS 2022, 4–6 September, 2022.
Questions
- What is known about the impact of vitamin D status on susceptibility to acute respiratory infections (ARI)? (0:11)
- What were the aims, design and eligibility criteria of your study? (1:14)
- What were the outcome measures of the study and how well were they achieved? (1:54)
- Why do you think that vitamin D replacement failed to reduce risk of all-cause ARI or COVID-19 in this study? (2:51)
- What questions remain unanswered and what future studies are planned? (4:05)
Disclosures: Adrian Martineau discloses receiving grant/ research support from Barts Charity (ref. MGU0459), Pharma Nord Ltd, the Fischer Family Foundation, DSM Nutritional Products Ltd, the Exilarch’s Foundation, the Karl R Pfleger Foundation, the AIM Foundation, Synergy Biologics Ltd, Cytoplan Ltd, the UK National Institute for Health Research Clinical Research Network, the HDR UK BREATHE Hub, Thornton & Ross Ltd, Warburtons Ltd, Mr Matthew Isaacs (personal donation), and Hyphens Pharma Ltd; serving on advisory boards for Qiagen Ltd; and receiving honoraria from DSM Nutritional Products Ltd, Linus Pauling Institute.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ERS meeting 2022.
